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Background: Little is known concerning the degree to which initiation of sildenafil for pulmonary arterial
hypertension (PAH) impacts patterns of healthcare utilization and costs.
Methods: Using a large US health insurance claims database, we identified all patients with evidence of PAH (ICD-
9-CM diagnosis codes 416.0, 416.8) who received sildenafil between 1/1/2005 and 9/30/2008. Date of the first-noted
prescription for sildenafil was designated the “index date,” and claims data were compiled for all study subjects for
6 months prior to their index date (“pretreatment”) and 6 months thereafter (“follow-up”); patients with incomplete
data during either of these periods were excluded. Healthcare utilization and costs were then compared between
pretreatment and follow-up for all study subjects.
Results: A total of 567 PAH patients were identified who began therapy with sildenafil and met all other study
entry criteria. Mean (SD) age was 52 (10) years; 73% were women. Healthcare utilization was largely unchanged
between pretreatment and follow-up, the only exceptions being decreases in the mean number of emergency
department visits (from 0.7 to 0.5 per patient; p < 0.01) and the percentage of patients hospitalized (from 35% to
29%; p = 0.01). The mean cost of all PAH-related medication was $7139 during pretreatment and $14,095 during
follow-up (sildenafil cost during follow-up = $5236); exclusive of PAH-related medications, however, total healthcare
costs decreased modestly (from $30,104 to $27,605) (p < 0.01 for all comparisons).
Conclusions: The cost of sildenafil therapy may be partially offset by reductions in other healthcare costs.
Keywords: Pulmonary arterial hypertension, Primary pulmonary hypertension, Sildenafil, PDE5, Phosphodiesterase
type 5, Health expenditure, UtilizationBackground
Pulmonary arterial hypertension (PAH) is characterized
by a pathological narrowing of the pulmonary arterioles
and small arteries, which causes elevated pulmonary
vascular resistance and increased pressure in the pul-
monary arteries and eventually results in the develop-
ment of right ventricular failure and death [1,2].
Dyspnea, fatigue, chest pain, and syncope are the princi-
pal presenting symptoms of PAH [3]. The disease is one
form of pulmonary hypertension (broadly defined as
increased pressure in the pulmonary arteries, capillaries,
or veins). In recent classification schemes for pulmonary* Correspondence: aberger@pai2.com
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other specific diseases (Group 2 includes patients with
pulmonary hypertension primarily due to left heart dis-
ease, Group 3 comprises those with pulmonary hyper-
tension due to chronic pulmonary disease, Group 4
includes cases of chronic thromboembolic pulmonary
hypertension, and Group 5 includes miscellaneous types
of pulmonary hypertension that do not fit into the other
four categories). In epidemiologic studies, the most com-
mon types of PAH (in order of decreasing frequency)
are: (1) idiopathic; (2) PAH associated with connective
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wide, it is estimated that 130,000 to 260,000 persons
have PAH [10]. Mean age at diagnosis is >50 years, and
the disease is more common among women than men.
Most patients present with moderate-to-severe disease
and prognosis is poor; 5-year survival in the absence of
treatment is only about 50% [9].
The goal of therapy in PAH is to control symptoms of
the disease and hopefully slow its progression. Conven-
tional therapy has included the management of under-
lying or contributing factors, avoidance of pregnancy,
early treatment of respiratory tract infections, and
immunization against pneumococcal disease and influ-
enza [11]. Calcium channel blockers at high doses also
have been an important component of conventional
therapy in the small percentage of PAH patients who re-
spond to such therapy.
In recent years, a number of targeted pharmacothera-
pies have been introduced for the treatment of PAH [12].
There are three main classes of such agents, which act
on three main intracellular pathways: (1) prostaglandin/
prostacyclin analogues (e.g., intravenous epoprostenol,
nebulized or intravenous iloprost); (2) endothelin receptor
antagonists (e.g., oral bosentan); and (3) phosphodiesterase-
type 5 (PDE-5) inhibitors (e.g., oral sildenafil). These tar-
geted therapies have been shown to improve exercise
capacity, hemodynamics, symptoms, and health-related
quality of life [13].
Sildenafil (RevatioW) is a PDE-5 inhibitor that was
approved for the treatment of PAH (to improve exercise
capacity) in 2005 in the US and the European Union,
and then in 2009, to delay clinical worsening (US only)
[14]. While the efficacy and safety of sildenafil are well
established, comparatively little is known about the
effects of such therapy on healthcare utilization and
costs in “real-world” settings. Our study examined this
issue using health insurance claims data.
Methods
Data source
Data were obtained from the Medstat MarketScan Com-
mercial Claims and Encounters Database. The database is
comprised of facility, professional-service, and retail (i.e.,
outpatient) pharmacy claims from a variety of private
insurers, providing healthcare coverage to approximately
15 million persons annually throughout the US. All
patient identifiers in the database have been fully
encrypted, and the database is fully compliant with the
Health Insurance Portability and Accountability Act
of 1996. As no patient or provider contact was made,
and patient information was de-identified; institutional
review board (IRB) approval was not required.
Information available for each facility and professional-
service claim includes date and place of service,diagnoses (in International Classification of Diseases, 9th
revision, Clinical Modification [ICD-9-CM] format), pro-
cedures (in ICD-9-CM [selected plans only], Current
Procedural Terminology 4th Edition, and Healthcare
Common Procedure Coding System formats), provider
specialty, and charged and paid amounts. Data available
for each retail pharmacy claim include the drug dis-
pensed (in National Drug Code format), the dispensing
date, and the quantity dispensed and number of days of
therapy supplied (selected plans only). All claims include
a charged amount; the database also provides paid (i.e.,
reimbursed, including patient deductible, copayment,
and/or coinsurance) amounts.
Selected demographic and eligibility information is
also available, including age, gender, geographic region,
coverage type, and the dates of insurance coverage. All
patient-level data can be arrayed in chronologic order to
provide a detailed, longitudinal profile of all medical and
pharmacy services used by each plan member. The data-
base for this study encompassed the period, January 1,
2005 through September 30, 2008 (“study period”).
Study sample
The source population for our study consisted of all per-
sons with any inpatient claims, or two or more out-
patient claims at least 30 days apart, with a diagnosis of
pulmonary hypertension (ICD-9-CM diagnosis codes
416.0 [primary pulmonary hypertension] or 416.8 [sec-
ondary pulmonary hypertension]) between January 1,
2005 and September 30, 2008. We included patients
with either of these diagnosis codes (i.e., primary or sec-
ondary pulmonary hypertension) to ensure complete
capture of all those with PAH, since the ICD-9-CM cod-
ing system does not coincide with contemporary classifi-
cation schemes for pulmonary hypertension. Among
these patients, we then identified those with one or
more pharmacy claims for Revatio, the commercial
name of sildenafil that is indicated for the treatment of
PAH (sildenafil is also sold under the brand name of
ViagraW for erectile dysfunction; the dosages of Revatio
and Viagra differ, however, as do the number of pills
supplied per respective prescription). The date of each
patient’s first-noted claim for Revatio was designated his
or her “index date”, and claims data were compiled for
all study subjects for 6 months prior to their index date
(“pretreatment”) and 6 months thereafter (“follow-up”).
(Revatio is indicated only for the treatment of PAH [14],
we therefore assumed that it was initiated only for this
disease among patients in our study sample, and conse-
quently did not require that the diagnostic evidence of
PAH occur prior to the index date.) Patients were
excluded from the study sample if they: (1) had incom-
plete data during pretreatment or follow-up; (2) received
Viagra during pretreatment; (3) were aged <18 years as
Table 1 Comorbidities of interest
Comorbidity Definition
Connective tissue diseases ICD-9-CM diagnoses 710.0, 710.1,
714.X, 710.3, 710.4
Congenital heart diseases ICD-9-CM diagnoses 745.3, 745.4,
745.5, 745.6, 747.0
HIV/AIDS ICD-9-CM diagnoses 042, 079.53, V08
Depressive disorders ICD-9-CM diagnoses 311, 296.2X,
296.3X, 296.5X, 296.82, 300.4, 298.0,
309.0, 309.28, 309.1
Anxiety disorders ICD-9-CM diagnoses 300.XX, 301.XX,
309.21
Sleep disorders ICD-9-CM diagnoses 780.57, 780.50,
780.51, 780.53, 307.4X, 780.5X, V69.4
Lung disease
Asthma ICD-9-CM diagnoses 493.XX
Chronic obstructive
pulmonary disease
ICD-9-CM diagnoses 491.XX, 492.XX,
496.XX
Pulmonary fibrosis ICD-9-CM diagnoses 515, 516.3
Cerebrovascular disease ICD-9-CM diagnoses 430-438.XX
Coronary heart disease ICD-9-CM diagnoses 410-414.XX
Atrial fibrillation ICD-9-CM diagnoses 427.3
Congestive heart failure ICD-9-CM diagnoses 428.XX
Peripheral vascular disease ICD-9-CM diagnoses 440.2X, 440.3X,
443.9X, 444.22
Hemtaological conditions ICD-9-CM diagnoses 282.6, 282.49,
289.6, 205.1X
Liver disease ICD-9-CM diagnoses 572.3, 006.3,
070.22, 070.32, 070.33, 070.44,
070.54, 456.0-456.21, 570-572.29,
572.4- 573.9, 996.82, V42.7
Renal disease ICD-9-CM diagnoses 293.9, 294.8,
276.0-276.9, 458.21, 567.XX,
584.XX-586.XX, 792.5, 996.1, 996.62,
996.56, 996.68, 996.73, 999.2, 999.3,
999.9, V45.1, V56.0, V56.1, V56.2,
V56.3X, V56.8, E87.02, E87.91;
ICD-9-CM procedures 39.42, 39.43,
39.93, 39.94, 39.9





Neoplasms ICD-9-CM diagnosis 140.XX-209.XX,
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index date if they were not enrolled in a Medicare risk-
sharing (i.e., capitated) plan. While we excluded patients
who received Viagra in the pretreatment period, receipt
of Viagra during follow-up was not an exclusion criter-
ion (i.e., study subjects were required to have initiated
therapy with Revatio, but could have switched to Viagra
for reasons related to dosage or cost).
Measures and analyses
We examined selected demographic and clinical charac-
teristics of study subjects, including the number with
various comorbidities (Table 1), based on information
during the 6-month pretreatment period. Patients were
assumed to have a given condition if they had evidence
during pretreatment of either one or more hospitaliza-
tions, or two or more outpatient claims at least 30 days
apart, with a corresponding diagnosis code and/or pre-
scription. The Charlson comorbidity index also was cal-
culated [15].
Levels of healthcare utilization and cost were exam-
ined during pretreatment and follow-up, including ser-
vices and medications related to the treatment of PAH.
PAH-related services were identified based on claims for
medical treatment with an ICD-9-CM diagnosis code for
PAH. PAH-related medications were assumed to consist
of PDE-5 inhibitors (including both Revatio and Viagra),
prostaglandin/prostacyclin analogues, endothelin recep-
tor antagonists, nitric oxide/nitric oxide donors, cal-
cium channel blockers, oral anticoagulants/antiplatelets,
diuretics, oxygen, and cardiac glycosides. (While many
of these medications are prescribed for conditions other
than PAH [e.g., calcium channel blockers for hyperten-
sion and coronary artery disease], we designated them as
“PAH-related” given their potential for use in the treat-
ment of PAH).
The statistical significance of differences in continuous
measures was assessed using paired t-tests and Wilcoxon
signed-rank tests for measures that were normally and
non-normally distributed, respectively; for categorical
data, McNemar’s and Bowker’s tests were used, as appro-
priate. All analyses were conducted using PC-SASW v.8.4.230.XX-238.XX
HIV/AIDS: Human immunodeficiency virus/Acquired Immune Deficiency
Syndrome.Results
We identified a total of 567 patients with evidence of
PAH who began therapy with sildenafil and satisfied all
other entry criteria (Table 2). Eighty-six percent of
patients in the study sample had encounters with ICD-
9-CM diagnoses of both primary pulmonary hyperten-
sion (416.0) and secondary pulmonary hypertension
(416.8) during the study period; the remaining 14% had
claims only for primary (4.3%) or secondary (9.7%) pul-
monary hypertension. Mean (standard deviation) age ofstudy subjects was 52.3 (9.8) years; 72.7% were women
(Table 3). The percentage of study subjects with selected
comorbidities was as follows: connective tissue disease,
18.3%; congenital heart disease; 4.1%; chronic obstructive
pulmonary disease, 19.0%; pulmonary fibrosis, 12.2%;
and congestive heart failure, 23.6%.
Use of most PAH-related medications increased between
pretreatment and follow-up, including prostaglandin/
Table 2 Sample selection
Criteria Number of
patients
Total number of patients with ≥1 inpatient claims,
or ≥2 outpatient claims at least 30 days apart,
with diagnosis of PAH during study period* and
22101
One or more pharmacy claims for Revatio during
study period and
1116
≥6 months enrollment prior to index date** and 899
Eligible for medical and pharmacy benefits for
duration of study period and
899
Were aged ≥18 years as of index date and 856
Were aged <65 years as of index date or 856
Were aged ≥65 years as of index date and enrolled
in Medicare
856
Had total costs≥ $0 and 855
Had no receipt of Viagra during pre-index period and 793
Had ≥6 months enrollment following index date** 567
*Spanning January 1, 2005 to end of database.
**Defined as the date of the first-noted claim for Revatio.
Table 3 Demographic and clinical characteristics of study
subjects (N = 567*)
Characteristic Value
Mean (SD) age, y 52.3 (9.8)
Number (%) women 412 (72.7)
Comorbidities (n [%])
Connective tissue diseases 104 (18.3)
Congenital heart diseases 23 (4.1)
HIV/AIDS 1 (0.2)
Depressive disorders 29 (5.1)
Anxiety disorders 8 (1.4)
Sleep disorders 83 (14.6)
Lung disease
Asthma 33 (5.8)
Chronic obstructive pulmonary disease 108 (19.0)
Pulmonary fibrosis 69 (12.2)
Any of above 172 (30.3)
Cerebrovascular disease 10 (1.8)
Coronary heart disease 68 (12.0)
Atrial fibrillation 46 (8.1)
Congestive heart failure 134 (23.6)
Peripheral vascular disease 9 (1.6)
Hematological conditions 8 (1.4)
Liver disease 44 (7.8)
Renal disease 72 (12.7)
Diabetes 91 (16.0)
Neoplasms 38 (6.7)
Mean (SD) Charlson comorbidity index 1.0 (1.1)
PAH: Pulmonary arterial hypertension; HMO: Health maintenance organization;
PPO: Preferred provider; HIV/AIDS: Human immunodeficiency virus/Acquired
Immune Deficiency Syndrome.
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agents during pretreatment vs 11.1% during follow-up
[p = 0.01]), endothelin receptor antagonists (27.5% to
31.9% [p = 0.01]), oral anticoagulants (34.0% to 41.3%
[p < 0.01]), diuretics (61.4% to 68.3% [p < 0.01]), and car-
diac glycosides (16.6% to 19.0% [p = 0.03]) (Figure 1).
Use of calcium channel blockers declined (from 34.9% to
30.0%) (p < 0.01). There were few statistically significant
differences in healthcare utilization between pretreat-
ment and follow-up, the only exceptions being declines
in the mean number of emergency department (ED) vis-
its per patient (from 0.7 to 0.5 per patient; p < 0.01) and
the percentage of patients hospitalized (from 35.1% to
28.9%; p = 0.01) (Table 4).
The mean cost of PAH-related medication increased
from $7139 during pretreatment to $14,095 during
follow-up (p < 0.01). The cost of PDE-5 inhibitors was
$5236 during follow-up, almost all of it attributable to
Revatio (5 patients had evidence of receipt of Viagra; 3
patients, tadalafil). Mean total healthcare costs increased
from $37,243 during pretreatment to $41,700 during
follow-up; exclusive of the cost of PAH-related pharma-
cotherapy, mean total healthcare costs declined from
$30,104 to $27,605 (both p < 0.01) (Table 5). Significant
reductions were noted in the mean cost of physician
office visits (from $2088 to $1935), other outpatient vis-
its (from $6226 to $5490), and emergency department
visits (from $355 to $310) (all p < 0.01). There was a
nominal, albeit not statistically significant, decline in the
mean cost of hospitalization—from $13,743 during pre-
treatment to $11,602 during follow-up (p = 0.18), most
likely reflective of the aforementioned decline in the per-
centage of patients admitted to hospital.Discussion
Mean total healthcare costs during the six-month period
following initiation of sildenafil therapy were higher than
they were in the period immediately preceding the start
of such therapy, due largely to increases in the cost of
PAH-related pharmacotherapy. Exclusive of the cost of
pharmacotherapy, mean total healthcare costs declined
by about $2500, primarily as a result of significant
reductions in the cost of physician office visits (−$153),
other outpatient visits (−$736), and emergency depart-
ment visits (−$45).
Since the database that we used does not contain any
information on clinical effectiveness per se (e.g., six-
minute walk test, cardiopulmonary hemodynamics), our
study provides no direct evidence thereof for sildenafil.
We believe, however, that our study nonetheless pro-
vides some indirect evidence of its effectiveness, if one






































Figure 1 Use of PAH-related pharmacotherapy during pre- and post-index periods. *Excluding sildenafil. PDE-5: Phosphodiesterase type-5
inhibitor; PG/PGI2: Prostaglandin/prostacyclin analogues; ETRA: Endothelin-receptor antagonist; CCB: Calcium-channel blocker; AC: Anticoagulant.
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that the cost of PAH-related inpatient and outpatient
care (i.e., exclusive of the cost of PAH-related pharmaco-
therapy) declined would appear to be consistent with the
hypothesis that the efficacy of sildenafil is manifested in
clinical practice via reductions in the costs of PAH-
related services [13,16-24]. Our finding that initiation of
sildenafil therapy appears to be coupled in many patients
with increased use of other PAH-related medications is
not surprising in a progressive disease such as PAH.
Of course, there are other possible explanations for
the reductions in the cost of PAH-related care that we
observed. For one, the use of other PAH-related medica-
tions, such as prostaglandin/prostacyclin analogues (e.g.,
iloprost) and endothelin-receptor antagonists (e.g.,
bosentan), also increased significantly during follow-up.
The decline in healthcare costs that we observed may
simply be a result of better tailoring of medication regi-
mens to patients’ needs and not to the use of sildenafil
alone. Cost reductions also could reflect regression to
the mean, if there is lability in signs and symptoms and
clinicians are more likely to modify medication regimens
when patients are doing poorer clinically (e.g., experien-
cing exacerbation). Given the scant clinical data available
to us, the precise reason(s) for observed reductions in
healthcare costs following initiation of sildenafil therapy
must remain conjectural.
Certain limitations of our study warrant mention. We
could not definitively identify patients with PAH because
ICD-9-CM coding for pulmonary hypertension predatescurrent classification schemes. We included patients
who received either of the two principal diagnosis codes
for pulmonary hypertension (416.0, 416.8) to ensure
complete capture of all patients with PAH. Although
90% of study subjects had at least one claim for primary
pulmonary hypertension (presumably, idiopathic or her-
itable PAH), most (86%) also had claims for other forms
of pulmonary hypertension, which could include PAH
associated with other disorders (e.g., PAH due to con-
nective tissue disease), as well as other, non-PAH, pul-
monary hypertension . The relatively high prevalence of
both congestive heart failure (CHF) (a common under-
lying disease in Group 2 pulmonary hypertension) and
chronic obstructive pulmonary disease (COPD) (a com-
mon underlying disease in Group 3 pulmonary hyper-
tension) in our study population (24% and 19%,
respectively) further suggests that some degree of mis-
classification may have occurred. Although it is possible
to have both PAH and COPD and/or CHF (right-heart
failure develops late in the course of PAH), the preva-
lence of both PAH and CHF or COPD is probably small,
which raises the possibility that a proportion of these
patients in our sample had Group 2 and Group 3 pul-
monary hypertension, respectively. We note, however,
that even if there were no overlap between patients with
CHF and those with COPD, and all patients with CHF
or COPD had secondary pulmonary hypertension, this
would account for only about one-half of all patients
with ICD-9-CM diagnosis codes for both primary and
secondary pulmonary hypertension.
Table 4 Use of healthcare services during pre- and post-index periods
Service Pre-index Post-index P-value
Outpatient services
Physician office visits
Number (%) with ≥1 visits 561 (98.9) 559 (98.6) 0.48
Number of visits
Mean (95% CI) 11.7 (11.1, 12.4) 12.1 (11.3, 12.9) 0.60
Median (IQR) 10 (6, 15) 10 (6, 16)
Other outpatient office visits
Number (%) with ≥1 visits 550 (97.0) 540 (95.2) 0.08
Number of visits
Mean (95% CI) 10.1 (9.4, 10.9) 10.3 (9.5, 11.1) 0.52
Median (IQR) 8 (5, 13) 8 (4, 14)
ED visits
Number (%) with ≥1 visits 194 (34.2) 140 (24.7) <0.01
Number of visits
Mean (95% CI) 0.7 (0.6, 0.8) 0.5 (0.4, 0.7) <0.01
Median (IQR) 0 (0, 1) 0 (0, 0)
Hospitalizations
Number (%) with ≥1 hospitalizations 199 (35.1) 164 (28.9) 0.01
Number of hospitalizations
Mean (95% CI) 0.5 (0.4, 0.6) 0.5 (0.4, 0.5) 0.18
Median (IQR) 0 (0, 1) 0 (0, 1)
Length of stay
All patients
Mean (95% CI) 4.3 (3.5, 5.1) 3.9 (3.0, 4.7) 0.06
Median (IQR) 0 (0, 5) 0 (0, 3)
Patients with ≥1 hospitalizations
Mean (95% CI) 8.8 (7.3, 10.3) 7.8 (6.2, 9.5) 0.06
Median (IQR) 5 (0, 11) 3 (0, 9)
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ICD-9-CM diagnosis codes for primary and secondary
pulmonary hypertension had PAH. All study subjects
had to have evidence of receipt of sildenafil, which has
been approved for the treatment of PAH but not other
classes of pulmonary hypertension. We acknowledge
that in clinical practice, physicians may prescribe drugs
approved exclusively for PAH for patients with other
forms of pulmonary hypertension, but note that the in-
clusion of such patients in our study sample should have
imparted a conservative bias to our findings because the
costs of sildenafil therapy would have been incurred
without the benefits in terms of decreased utilization
and cost of healthcare services. The degree to which
misclassification actually occurred in our study must re-
main conjectural.
Finally, we note that we did not include a concurrent
control group as part of our study, and that there arewell-established threats to validity associated with these
types of research designs. While we were mindful of the
problems posed by the use of a study design that did not
utilize a concurrent control, we were similarly concerned
about the comparability of any population of control
subjects that we might have designated. Specifically, it
would have required that we identify a group of patients
beginning therapy with something other than a PDE-5
inhibitor, and then compare changes in healthcare costs
(i.e., pre-treatment versus post-initiation) between these
patients and those beginning therapy with Revatio.
Underlying differences in disease severity and other po-
tentially important clinical parameters, however, could
introduce confounding and bias into such a comparison
if not adequately controlled for in the analyses. In the
end, we elected not to include concurrent controls in
our study due these problems. This significant limitation
of our study design should be borne in mind, however,






inhibitors 2 (0, 4) 5,236 (4963, 5510) <0.01
Prostaglandin/prostacyclin
analogues 1,569 (934, 2204) 2,271 (1574, 2969) <0.01
Endothelin receptor antagonists 4,686 (4009, 5363) 5,613 (4867, 6359) <0.01
Calcium channel blockers 79 (66, 92) 71 (59, 83) 0.14
Oral anticoagulants 31 (26, 36) 41 (35, 47) <0.01
Diuretics 61 (52, 71) 75 (64, 87) <0.01
Oxygen 708 (601, 816) 784 (684, 883) <0.01
Cardiac glycosides 4 (3, 5) 5 (4, 6) <0.01
Any of above 7,139 (6122, 8156) 14,095 (12982, 15209) <0.01
All other 2,714 (2041, 3386) 2,876 (2323, 3428) 0.10
Total pharmacotherapy 9,853 (8614, 11091) 16,971 (15758, 18184) <0.01
Outpatient services
Physician office visits 2,088 (1807, 2368) 1,935 (1603, 2267) <0.01
Other outpatient office visits 6,226 (5060, 7391) 5,490 (4245, 6736) <0.01
ED visits 355 (270, 440) 310 (209, 411) <0.01
Total outpatient services 8,668 (7439, 9898) 7,735 (6401, 9070) <0.01
Hospitalizations 13,743 (9745, 17741) 11,602 (8443, 14762) 0.18
All other 4,979 (3627, 6332) 5,391 (3920, 6863) 0.96
Total
Exclusive of PAH-related
medications 30,104 (25422, 34787) 27,605 (23536, 31674) <0.01
Inclusive of PAH-related
medications 37,243 (32467, 42020) 41,700 (37470, 45931) <0.01
*All values are mean (95% CI) total healthcare costs, $.
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rigorously the true effects of Revatio therapy for PAH.Conclusions
In conclusion, while total healthcare costs increased
among PAH patients initiating therapy with sildenafil,
the cost of such therapy may be partially offset by reduc-
tions in other healthcare costs—specifically, those for
outpatient and inpatient services.
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